Drug-resistant tuberculosis treatment
Description
This e-learning course is a comprehensive, self-paced, online course that follows the content of the WHO operational handbook on tuberculosis. Module 4: Treatment – drug-resistant tuberculosis treatment. The main focus of the e-course is programmatic; clinical aspects are only discussed when relevant to specific topics.
The e-course comprises 11 sections and a final assessment and uses a combination of short video lectures, exercises, quiz questions and additional reading materials.
Course Index:
- Introduction to the e-learning course
- Rationale for national TB programmes to implement and scale up treatment of DR-TB
- Key considerations in DR-TB treatment
- Treatment regimen for isoniazid-resistant rifampicin-susceptible TB
- Shorter, all-oral bedaquiline-containing treatment regimen
- Longer treatment regimens for multidrug-resistant TB (MDR-TB)/ rifampicin-resistant TB (RR-TB)
- The bedaquiline, pretomanid and linezolid (BPaL) regimen for MDR-TB or RR-TB with additional fluoroquinolone resistance
- Adjuncts to MDR-TB treatment
- Patient support to enable adherence to treatment
- Programmatic implementation of regimens for MDR-TB and RR-TB
- Assessing drug-resistant TB programme implementation effectiveness
- Final assessment